Interaction of natriuretic peptide levels and ejection fraction on outcomes with dapagliflozin and empagliflozin in heart failure

Javed Butler^{1

2}, Tariq Jamal Siddiqi², Faiez Zannad³, João Pedro Ferreira^{3

4}, Gerasimos Fillipatos⁵, Stefan D Anker⁶, Milton Packer^{7

8}

Affiliations

¹ Baylor Scott and White Research Institute, Dallas, TX, USA.
² Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
³ Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
⁴ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
⁵ National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
⁶ Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁷ Baylor University Medical Center, Dallas, TX, USA.
⁸ Imperial College, London, UK.

Free article

Javed Butler et al. Eur J Heart Fail. 2023 May.

Free article

. 2023 May;25(5):767-769.

doi: 10.1002/ejhf.2854. Epub 2023 May 3.

Javed Butler^{1

2}, Tariq Jamal Siddiqi², Faiez Zannad³, João Pedro Ferreira^{3

4}, Gerasimos Fillipatos⁵, Stefan D Anker⁶, Milton Packer^{7

8}

¹ Baylor Scott and White Research Institute, Dallas, TX, USA.
² Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
³ Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
⁴ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
⁵ National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
⁶ Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
⁷ Baylor University Medical Center, Dallas, TX, USA.
⁸ Imperial College, London, UK.

No abstract available

References

1. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400:757-67.
1. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28:1956-64.
1. Anker SD, Siddiqi TJ, Filippatos G, Zannad F, Ferreira JP, Pocock SJ, et al. Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions. Eur J Heart Fail. 2022;24:1400-5.
1. Ezekowitz JA, O'Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: Vericiguat Heart Failure with Reduced Ejection Fraction study. JACC Heart Fail. 2020;8:931-9.
1. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al.; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384:105-16.